43887 Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials.

Details

Language :

English

ISSN :

01909622

Volume :

89

Issue :

3

Database :

Supplemental Index

Journal :

Journal of the American Academy of Dermatology

Publication Type :

Academic Journal

Accession number :

172869415

Full Text :

https://doi.org/10.1016/j.jaad.2023.07.145